On the basis of these preclinical results, we can hypothesize that MMP9 released by tumor-infiltrating neutrophils may increase VEGFA availability in the glioblastoma microenvironment, exceeding the ability of bevacizumab to trap it. This evidence concerns the gene MMP9 and glioblastoma.